µ±Ç°Î»ÖÃ: Ê×Ò³ > ÆÚ¿¯ > ¡¶ÖйúÏÖ´úÓ¦ÓÃҩѧ¡· > 2000ÄêµÚ2ÆÚ
񅧏:10496761
ÑÎËá°Âµ¤Î÷¡ÓëÆäËüÒ©ÎïÅäÎéµÄÎȶ¨ÐÔ
http://www.100md.com ¡¶ÖйúÏÖ´úÓ¦ÓÃҩѧ¡· 2000ÄêµÚ2ÆÚ
     ×÷ÕߣºÍõÃ÷ÖÙ

    µ¥Î»£ººþ±±Ïå·®ÊÐÖÐÐÄҽԺҩѧ²¿ Ïå·® 441021

    ¹Ø¼ü´Ê£º

    ÖйúÏÖ´úÓ¦ÓÃҩѧ000233 ÑÎËá°Âµ¤Î÷¡(Ondansetron hydrochloride,Ond)ΪӢ¹ú¸ðÀ¼Ëع«Ë¾1989Ä꿪 ·¢³É¹¦µÄ¸ß¶ÈÑ¡ÔñÐÔ5-HT3ÊÜÌåÞ׿¹¼Á£¬ÉÌÆ·ÃûΪÊิÄþ(zofran)£¬ÓÃÓÚ·ÅÁÆ¡¢»¯ÁÆʱÕò ÍÂЧ¹ûÏÔÖø¡£ÎÒ¹úÄþ²¨ÌìºâÖÆÒ©³§×Ô1996ÄêÕýʽÉú²ú£¬ÉÌÆ·ÃûÊ൤¡£ÓÉÓÚÖ×Áö»¼ÕßÓÃÒ©µÄ¸´ ÔÓÐÔ£¬Ðí¶àѧÕß¾¹ÏàÑо¿ÁËOnd³£ÓÃŨ¶È(0.03¡«0.3mg/ml)ÏÂÓëÆäËüÒ©ÎïµÄÅäÎéÐÔ£¬±¾ÎÄÓè ÒÔ×ۺϽéÉÜ(¼û±í1)£¬ÒÔÀûÓÃÒ©²Î¿¼¡£

    ±í1 ÑÎËá°Âµ¤Î÷¡ÓëÆäËüÒ©ÎïÅäÎéµÄÎȶ¨ÐÔ ÅäÎéÒ©Îï

    Å¨¶È/mg.ml-1
, http://www.100md.com
    ÈÜý

    OndŨ¶È

    /mg.ml-1

    ÈÝÆ÷

    Öü´æÌõ¼þ

    ¹Û²ì

    Ö¸±ê

    Îȶ¨

    Ê±¼ä

    ²Î¿¼

    ÎÄÏ×

    10%ÆÏÌÑÌÇ(10%GS)

, °ÙÄ´Ò½Ò©     0.08

    d

    ÊÒÎÂ

    Y

    >24h

    1

    5%ÆÏÌÑÌÇ(5%GS)

    0.03£¬0.3

    -20¡æ,5¡æ,25¡æ

    Y

    > 24h

    2£¬3

    ÉúÀíÑÎË®(NS)
, °ÙÄ´Ò½Ò©
    0.03£¬0.08£¬0.3

    d

    -20¡æ£¬5¡æ£¬25¡æ

    Y

    >24h

    1£¬2

    ÆÏÌÑÌÇÂÈ»¯ÄÆ×¢ÉäÒº

    0.08

    d

    ÊÒÎÂ

    Y

    >24h

    1
, °ÙÄ´Ò½Ò©
    ¸´·½ÂÈ»¯ÄÆ×¢ÉäÒº

    0.08

    d

    ÊÒÎÂ

    Y

    >24h

    1

    ÑÎËᰢùËØ

    0.1£¬2

    5%GS

    0.03£¬0.3

    a

    ÊÒΣ¬ÈÕ¹âµÆÏÂ
, °ÙÄ´Ò½Ò©
    Y

    >24h

    4

    °¢ÌÇ°ûÜÕ

    0.2£¬40

    5%GS

    0.03£¬0.3

    a

    ÊÒΣ¬ÈÕ¹âµÆÏÂ

    Y

    >24h

    4

    1¦¤
, °ÙÄ´Ò½Ò©
    ´ï¿¨°Íàº

    1£¬3

    5%GS

    0.03£¬0.3

    a,c

    4¡æ£¬30¡æ£¬ÈÕ¹âµÆ ÏÂ

    Y

    4¡«8h

    4£¬5

    ÒÀÍв´ÜÕ

    0.1£¬0.4

    5%GS

    0.03£¬0.3
, °ÙÄ´Ò½Ò©
    a

    ÊÒΣ¬ÈÕ¹âµÆÏÂ

    Y

    >24h

    4

    ¼×°±µûßÊ

    0.5£¬6

    5%GS

    0.03£¬0.3

    a

    ÊÒΣ¬ÈÕ¹âµÆÏÂ

    Y

    >24h
, http://www.100md.com
    4

    2¦¤

    ÁòË᳤´ºÐ¼î

    0.014£¬0.028

    NS

    0.048£¬0.096

    a,c

    4¡æ£¬3 0¡æ

    Y

    >24h

    5

    »·Á×õ£°·

    0.3£¬2
, http://www.100md.com
    5%GS£¬NS

    0.05£¬0.4

    4¡æ£¬25¡æ

    Y

    >4d

    6£¬7

    ×Ïɼ´¼

    1.2

    5%GS

    0.3£¬7.29

    b

    23¡æ

    Y
, °ÙÄ´Ò½Ò©
    >4h

    8£¬9

    Ë³²¬

    0.200£¬0.455

    NS

    1.091£¬0.480

    a

    2¡«8¡æ£¬30¡æ

    Y

    >24h

    10

    àçÌæßß

    1
, °ÙÄ´Ò½Ò©
    5%GS

    1

    b

    23¡æ£»¸ß¡¢µÍÕնȹâ

    X

    >4h

    11

    ßßÀ­Î÷ÁÖ-Ëûßò°Í̹

    40-5£¬80-10

    NS

    0.03£¬0.1£¬0.3

    b

    23 ¡æ,ÊÒ¹â
, °ÙÄ´Ò½Ò©
    Y

    >4h

    12

    °±ÇúÄÏ

    20£¬40

    5%GS

    0.015£¬0.15£¬1

    b

    25¡æ

    X

    >4h

    13£¬14

    Í·æßËþÆ붨(̼ËáÄÆÑÎ)
, °ÙÄ´Ò½Ò©
    20

    5%GS

    0.015£¬0.15

    b

    25¡æ

    X

    >4h

    13

    Í·æßßòßøÄÆ

    10

    5%GS

    0.015£¬0.15

    b
, http://www.100md.com
    25¡æ

    X

    >4h

    1 3

    ·ú¿µßò

    1

    NS

    0.015£¬0.15

    b

    25¡æ

    X

    >4h

    13

, http://www.100md.com     3¦¤

    Ã×ŵÅäÄÜ(meropenam)

    1£¬20£¬50

    NS

    1

    b,d

    ÊÒΣ¬ÈÕ¹âµÆ ÏÂ

    X

    0(³Áµí)

    15

    Í·æßÃÀßòÄÆ

    100

    NS
, °ÙÄ´Ò½Ò©
    2

    a,b,c

    ÊÒΣ¬ÈÕ¹âµÆÏÂ

    X

    >1h

    16

    ÁòËáÂð·È

    1

    NS

    0.1£¬1.0

    4¡æ,22¡æ

    X

    >31d
, °ÙÄ´Ò½Ò©
    17

    ÑÎËá¶þÇâÂð·È

    0.5

    NS

    0.1£¬1.0

    4¡æ,22¡æ

    X

    >31d

    17

    remifentanil hydrochloride

    0.025£¬0.25

    NS

, http://www.100md.com     1

    b

    23¡æ

    X

    >4h

    18

    ±½Ì¼Ëá˳°¢Çú¿âï§

    0.1£¬2£¬5

    5%GS

    1

    b

    23¡æ£¬¸ßµÍÕնȹâ

    X
, °ÙÄ´Ò½Ò©
    >4h

    19

    TPN(»òPN)

    NS

    0.03£¬0.3£¬1

    b

    ÊÒΣ¬ÈÕ¹âµÆÏÂ

    Y

    >4 8h

    20£¬21

    4¦¤

    CsA

    1.5
, °ÙÄ´Ò½Ò©
    NS

    0.32

    b,d

    ÊÒΣ¬ÈÕ¹âµÆÏÂ

    X

    ?

    22

    ÑÎËá¶à°Í°·

    0.8

    NS

    0.32

    b,d

    ÊÒΣ¬ÈÕ¹âµÆÏÂ
, °ÙÄ´Ò½Ò©
    X

    >5h

    22

    ¸ÎËØÄÆ

    100u/ml

    NS£¬5%GS

    0.32

    b,d

    ÊÒΣ¬ÈÕ¹âµÆÏÂ

    X

    >5h

    22

    5¦¤
, °ÙÄ´Ò½Ò©
    Æ»¹ûÖ­¡¢éÙÖ­¡¢¹û¾Æ¡¢Ó£ÌÒ

    ÒûÁÏ¡¢Ì¼ËáÀàÈíÒûÁÏ

    0.067-2

    d

    -3¡«28¡æ

    Y

    >1h

    23£¬24

    ÑÎËáÀ×ÄáÌ涡

    0.2£¬2.0

    5%GS

    0.03£¬0.1£¬0.3
, °ÙÄ´Ò½Ò©
    b

    23¡æ

    Y

    >4h

    8£¬25

    6¦¤

    µØÈûÃ×ËÉ

    0.20£¬0.40

    NS£¬5%GS

    0.10£¬0.2£¬0.4£¬0.64[ HT6¡±¡½

    a

    2¡«6¡æ£¬23¡æ

    Y
, °ÙÄ´Ò½Ò©
    >48h

    26¡«28

    ÀÍÀ­Î÷ãú

    0.004

    5%GS

    0.016,0.08

    d

    25¡æ

    Y

    >24h

    26

    aldesleukin(ÖØ×é°×½éËØ-2)

    33800IU/ml
, °ÙÄ´Ò½Ò©
    5%GS

    0.7

    b

    ÊÒΣ¬ ÈÕ¹âµÆÏÂ

    Z

    >2h

    29

    amifostine

    10

    5%GS

    1

    b

    23¡æ
, °ÙÄ´Ò½Ò©
    X

    >4h

    30

    ×¢£ºa-Ö±½Ó»ìºÏÓÚPVC´üÄÚ£»b-Ä£ÄâÊäҺװÖÃY²¿µÈÌå»ý»ìºÏÖüÓÚPVC´üÖÐ £»c-ÔÚ¾Û ÒìÎì¶þÏ©ÊäÒº±ÃÒ©³ØÖУ»d-²£Á§ÈÝÆ÷£»X-Íâ¹Û£»Y-Íâ¹Û¼°º¬Á¿£»Z-Íâ¹Û¡¢º¬Á¿¼°ÉúÎïЧ¼Û£» 1¦¤-Ond¡¢ÑÎËᰢùËØ¡¢´ï¿¨°ÍàºÈýÒ©ÅäÎ飬30¡æ¡¢ÈÕ¹âµÆÏ¡¢PVC´üÄÚÎȶ¨4¡«8h£¬¾ÛÒìÎì ¶þÏ©ÊäÒº±ÃÒ©³ØÖÐÎȶ¨24hÒÔÉÏ£»2¦¤-Ond¡¢ÑÎËᰢùËØ¡¢ÁòË᳤´ºÐ¼îÈýÒ©ÅäÎ飬30¡æ£¬ÈÕ ¹âµÆÏ£¬a»òcÈÝÆ÷ÄÚ¾ùÎȶ¨24hÒÔÉÏ£»3¦¤-Ond 1mg/mlÓëÃ×ŵÅäÄÜ1mg/ml NSÈÜÒºÅäÎéÎÞ³Áµí £»4¦¤-CsAÔÚNSÖÐ΢Á£³¬ÏÞ£¬¼ÓÈëOndºó΢Á£ÎÞÃ÷ÏÔÔö¼Ó£»5¦¤-Ond¼ÓÈëÈȲè(75¡«85¡æ)Öм´ ¿Ì±ä»ì×Ç£»6¦¤-¸ßŨ¶ÈµÄOnd(0.64mg/ml)ÓëµØÈûÃ×ËÉ(0.40mg/ml)ÔÚ¾Û±ûϩעÉäÆ÷ÖгÁµí(µÍ Ũ¶ÈÎÞ)£¬¸÷Ũ¶ÈÔÚ¹¤Òµ¾ÛÖ¬CR3´üÄÚÎȶ¨48hÒÔÉÏ
, http://www.100md.com
    Óɸ½±í¿ÉÖª£¬OndÔÚ³£ÓÃŨ¶ÈÏ¿ÉÓëÐí¶àÒ©ÎïÅäÎéʹÓã¬Õâ¶Ô¼õÉÙ»¼Õß±»´©´Ì´ÎÊý¡¢Ò½ÎñÈË Ô±¹¤×÷Á¿¡¢»¼Õß²»±ØÒªÒºÌåÉãÈë¾ù¾ßÓлý¼«µÄÁÙ´²ÒâÒå¡£µ«Ó¦ÓÃÖÐӦעÒâÅäÎéÔÊÐíµÄŨ¶ÈºÍ Îȶ¨Ê±ÏÞ¡£OndÒ»°ã²»ÄÜÓëÃ×ŵÅäÄÜÅäÎ飬ÓëµØÈûÃ×ËÉÅäÎé²»ÄÜʹÓþ۱ûϩעÉäÆ÷¾ß£¬Ond¿É ¿Ú·þÓÃÒ©µ«²»ÄܼÓÈëÈȲèÖÐÒûÓã¬ÊÇ·ñÄÜÓë»·æßËØA(CsA)ÅäÎéÉв»Ã÷È·¡£

    ²Î¿¼ÎÄÏ×

    1£¬Ðì¼ÃƼ£¬ÕŹ𷼣¬Õżø.°Âµ¤Î÷¡עÉäÒºÔÚ4ÖÖ ÊäÒºÖеÄÎȶ¨ÐÔ.ÖйúÁÙ´²Ò©Ñ§ÔÓÖ¾£¬1997£¬6(1)¡Ã31.

    2£¬Bosso JA,Prince RA,Fox JL.Stability of on dansetron hydrochloride in injectable solutions at -20,5,25¡æ.Am J Hosp Pharm,19 92,49¡Ã2225.

    3£¬Thee SS,Jeona EWS,Chin A,et al.Stability of ondanstron hydrochloride stored in a disposable elastomeric in fu sion device at 4¡æ.Am J Hosp Pharm,1993,50¡Ã1920.
, °ÙÄ´Ò½Ò©
    4£¬ÍõÃ÷ÖÙÕª.ÑÎËá°Âµ¤Î÷¡ÓëÎåÖÖ¿¹Ö×ÁöÒ©µÄÅäÎé Îȶ¨ÐÔ.¹úÍâÒ½Ò©-ºÏ³ÉÒ©¡¢Éú»¯Ò©¡¢ÖƼÁ·Ö²á£¬1997£¬18(3)¡Ã189.

    5£¬Stewart JT,Warren FW,King DT,et al.Stability of ondansetron hydrochloride,doxorubicin hydrochloride,and dacar bazine or vincristine sulfate in elastomeric portable infusion devices and polyv inyl chloride bags.Am J Health-Syst Pharm,1997,54¡Ã915.

    6£¬Fleming RA,Olsen DJ,Savage PD,et al .Stability of ondansetron hydrochloride and cyclophosphamide.Am J Health- Syst Pharm,1995,52(5)¡Ã516.
, °ÙÄ´Ò½Ò©
    7£¬Ðì¼ÃƼ£¬Õżø£¬ÕŹð·¼.°ºµ¤Ë¾Çí×¢Éä¼ÁÓë»·Á× õ£°·×¢Éä¼ÁµÄÅäÎéÎȶ¨ÐÔ.ÖйúҽԺҩѧÔÓÖ¾£¬1997£¬17(6)¡Ã263.

    8£¬Burm JP,Jhee SS,Chin A,et al. Stability of paclitaxel with ondansetron hydrochloride or ranitidine hydrochlori de during simulated Y-site administration.Am J Hosp Pharm,1994,51¡Ã1201.

    9£¬Trissel LA,Martinez JF.Turbidimetric as sessment of the compatibility of taxol with 42 other drugs during simulated Y-s ite injection.Am J Hosp Pharm,1993,50¡Ã300.
, °ÙÄ´Ò½Ò©
    10£¬Henry DW,Marshall JL,Nazzaro D,et al .Stability of cisplatin and ondansetron hydrochloride in admixtures for continuo us infusion.Am J Health-Syst Pharm,1995,52¡Ã2570.

    11£¬Trissel LA,Martinez JF.Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.Am J H ealth-Syst Pharm,1996,53¡Ã1041.

    12£¬Chung KC,Moon YSK,Chin A,et al.Compa tibility of ondansetron hydrochloride and piperacillin sodium-tazobactam sodium during simulated Y-site administration.Am J Health-Syst Pharm,1995,52¡Ã1554.
, °ÙÄ´Ò½Ò©
    13£¬Bosso JA,Prince RA,Fox JL,et al.Compatibility of ondansetron hydrochloride with fluconazole,ceftazidime,azt reonam,and cefazolin sodium under simulated Y-site conditions.Am J Hosp Pharm,1 994,51¡Ã389.

    14£¬Trissel LA,Martinez JF.Compatibility of aztreona m with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm,1995,52¡Ã1086.

    15£¬Patel PR.Compatibility of meropenam with commonl y used injectable drugs.Am J Health-Syst Pharm,1996,53¡Ã2853.
, °ÙÄ´Ò½Ò©
    16£¬Hutchings SR,Rusho Wj,Tyler LS.Compatibility of cefmetazole sodium with commonly used drugs during Y-Site delivery.Am J Health -Syst Pharm,1996,53¡Ã2185.

    17£¬Trissel LA,Xu QY,Martinez JF,et al.C ompatibility and stability of ondansetron hydrochloride with morphine sulfate an d with hydromorphine hydrochloride in 0.9% sodium chloride injection at 4,22,and 32¡æ.Am J Hosp Pharm,1994,51¡Ã2142.

    18£¬Trissel LA,Gilbert DL,Martinez JF,et al.Compatibility of remifentanil hydrochloride with selected drugs during simul ated Y-site administration.Am J Health-Syst Pharm,1997,54¡Ã2192.
, °ÙÄ´Ò½Ò©
    19£¬Trissel LA,Martinez JF,Gilbert DL.Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administr ation.Am J Health-Syst Pharm,1997,54¡Ã1735.

    20£¬Kirkham JC,Rutherford ET,Cunningham GN,et al.Stability of ondansetron hydrochloride in a total parenteral nutrient a dmixture.Am J Health-Syst Pharm,1995,52¡Ã1557

    21£¬Trissel LA,Gilbert DL,Martinez JF,et al.Compatibility of parenteral nutrient solutions with selected drugs during si mulated Y-site administration.Am J Health-Syst Pharm,1997,54¡Ã1295.
, http://www.100md.com
    22£¬Najari Z,Rusho Wj.Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.Am J Health-Syst Pharm,19 97,54¡Ã181.

    23£¬Graham CL,Dukes GE,Fox JL,et al.Stab ility of ondansetron hydrochloride injection in extemporaneously prepared oral s olutions.Am J Hosp Pharm,1993,50¡Ã106.

    24£¬Yamreudeewong W,Danthi SN,Hill RA,et al.Stability of ondansetron hydrochloride injection in various beverages.Am J H ealth-Syst Pharm,1995,52¡Ã2011.
, http://www.100md.com
    25£¬Pompilio FM,Fox JL,Inagaki K,et al.S tability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazo le during simulated Y-site administration.Am J Hosp Pharm,1994,51¡Ã394.

    26£¬Mcguire TR,Narducci WA,Fox JL.Compatibility an d stability of ondansetron hydrochloride,dexamethasone,and lorazepam in injectab le solutions.Am J Hosp Pharm,1993,50(7)¡Ã1410.

    27£¬Evrard B,Ceccato A,Gaspard O,et al.S tability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride injection and in 5% dextrose injection.Am J Health-Syst Pharm, 1997,54¡Ã1065.
, http://www.100md.com
    28£¬Hagan RL,Mallett MS,Fox JL.Stability of ondanset ron hydrochloride and dexamethasone sodium phosphate in infusion bags and syring es for 32 days.Am J Health-Syst Pharm,1996,53¡Ã1431

    29£¬Alex S,Gupta SL,Minor JR,et al.Compa tibility and activity of aldesleukin(recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration:Evaluation of three metho ds.Am J Health-Syst Pharm,1995,52¡Ã2423.

    30£¬Trissel LA,Martinez JF.Compatibility of amifosti ne with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm,1995,52¡Ã2208.

    ÊÕ¸åÈÕÆÚ£º1998-04-06, http://www.100md.com